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http://dx.doi.org/10.1016/j.ccr.2014.05.004SUMMARYThe tumormicroenvironment plays a critical role in cancer progression, but the precisemechanismsbywhich
stromal cells influence the epithelium are poorly understood. Here we show that p62 levels were reduced in
the stroma of several tumors and that its loss in the tumormicroenvironment or stromal fibroblasts resulted in
increased tumorigenesis of epithelial prostate cancer cells. Themechanism involves the regulation of cellular
redox through an mTORC1/c-Myc pathway of stromal glucose and amino acid metabolism, resulting in
increased stromal IL-6 production, which is required for tumor promotion in the epithelial compartment.
Thus, p62 is an anti-inflammatory tumor suppressor that acts through the modulation of metabolism in the
tumor stroma.INTRODUCTION
Primary tumors are initiated as a result of the stepwise acquisi-
tion of genetic alterations within the epithelial compartment
(Shen and Abate-Shen, 2010). However, increasing evidence
supports the notion that the tumor microenvironment also plays
a critical role in cancer progression in many types of neopla-
sias, including prostate cancer (PCa), although relatively little is
known about the signaling pathways that mediate communica-
tion between the stromal and epithelial compartments (Ammir-
ante et al., 2010; Erez et al., 2010; Santos et al., 2009; Trimboli
et al., 2009). Inflammation and metabolism are two critical fac-
tors contributing to the protumorigenic properties of the stroma
(DeBerardinis and Thompson, 2012; Grivennikov et al., 2010;
Hanahan and Coussens, 2012; Metallo and Vander Heiden,
2013; Vander Heiden, 2013). Although not totally understood,Significance
Inappropriate activation of the stroma as a consequence of the
mation of epithelial tumor cells, thus facilitating the progressio
cancer as a model system, we show that the loss of the sign
response that leads to activation of cancer-associated fibrob
ciency in p62 results in reducedmTORC1activity andderegulat
the stroma is increasingly recognized as a potential source of th
metabolic reprogramming can decisively influence the tumorigsome evidence suggests that the metabolic state of the tumor
stroma can decisively influence the tumorigenic potential of
the tumor epithelial compartment (Lisanti et al., 2013). Here
we have addressed this fundamental biological question in the
context of p62 deficiency in the nonepithelial tumor compart-
ment. Our laboratory initially identified p62, also known as
sequestosome-1, as a scaffold protein for the atypical protein
kinase C isozymes and later implicated p62 in other cell stress
responses (Diaz-Meco and Moscat, 2012; Moscat and Diaz-
Meco, 2012; Moscat et al., 2007; Sanchez et al., 1998). p62
binds Raptor, a key component of the mTOR-orchestrated
nutrient-sensing complex and an important activator of anabolic
pathways that are instrumental in metabolic reprogramming
during cell transformation (Duran et al., 2011; Moscat and
Diaz-Meco, 2011). Nonetheless, nothing is known about the
signaling cascades that p62 regulates in stromal cells or totumorigenic process can potentiate the growth and transfor-
n of cancers toward more malignant stages. Using prostate
aling adaptor p62 in stromal cells triggers an inflammatory
lasts that enhances tumorigenesis in vitro and in vivo. Defi-
ion ofmetabolic pathways controlling inflammation.Because
erapeutic targets, this study suggests that targeting stromal
enic potential of the tumor epithelial compartment.
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Figure 1. p62 Levels Are Reduced in the Stroma of Human Prostate Tumors
(A) Representative examples of p62 staining of normal and primary prostate cancer (tumor) samples. The scale bars represent 25 mm.
(B) Quantification of p62 staining in the stroma of primary PCa tumors compared with normal; n = 22 (normal), n = 202 (PCa). Fisher’s exact test, p < 0.01.
(C) p62 levels are reduced upon PCa progression; n = 22 (normal), n = 70 (GS 2–6), n = 132 (GS 7–10). Chi-square test, p < 0.01.
(D) p62 mRNA levels in stroma of human cancer samples. Data were collected from public data sets of gene expression in the tumor stroma of several human
cancers: GSE34312 (prostate cancer), GSE9014 (breast cancer), and GSE35602 (colon cancer).
(E) FACS-sorted adult murine prostate cell lineages. Prostate basal, luminal, and stromal cells are LinSca-1+CD49fHi, LinSca-1CD49fLow, and LinSca-
1+CD49f, respectively.
(F) RT-PCR of specific markers for each prostate cell population (n = 3): p63 (basal), Nkx3.1 (luminal), and vimentin (stromal).
(G) RT-PCR for p62 in prostate cell populations (n = 3).
*p < 0.05, **p < 0.01, ***p < 0.001. Results are presented as mean ± SEM. See also Figure S1.
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Metabolic Suppressor Role of p62 in Stromawhat extent these pathways influence the epithelial-stromal
interaction in the tumor microenvironment. Cancer-associated
fibroblasts (CAFs) have been proposed to be key mediators of
the crosstalk between malignant tumor cells and their microen-
vironment (Barron and Rowley, 2012; Franco and Hayward,
2012). CAFs and the complex set of signaling molecules they
secrete generate an environment conducive to inflammation,
and this in turn maintains the protumorigenic status of the stro-
mal cells. Among these proteins, interleukin-1b (IL-1b), inter-
leukin-8, and interleukin-6 (IL-6) have been implicated as part
of the proinflammatory signature of the PCa stroma (Erez et al.,
2010; Franco and Hayward, 2012; Schauer et al., 2008). Further-
more, IL-6 has received increasing attention as a key proinflam-
matory and protumorigenic molecule in many types of cancer,
including PCa (Azevedo et al., 2011; De Marzo et al., 2007;
Guo et al., 2012; Schafer and Brugge, 2007). Here we address
the role of p62 in the stroma in the control of the inflammatory
environment in PCa.
RESULTS
p62 Expression Levels in the Tumor Microenvironment
The initial evidence suggesting that p62 plays a role in the regu-
lation of the tumor microenvironment in PCa came from the his-122 Cancer Cell 26, 121–135, July 14, 2014 ª2014 Elsevier Inc.tological analysis of a tissue panel comprising 202 primary
human PCa tumors, 8 metastases, and 22 adjacent normal
prostate tissue samples. This study revealed that p62 was ex-
pressed in the prostate epithelium and also in the stroma (Fig-
ure 1A). p62 protein levels were downregulated in the stroma
of human primary PCa tumors compared with the stroma of
normal samples (Figures 1A and 1B). Furthermore, when the tu-
mor samples were grouped on the basis of low Gleason score
(GS) (2–6) or high GS (7–10), p62 levels in the stroma were signif-
icantly reduced upon progression to the most aggressive stage
(Figure 1C). p62 was also overexpressed in the epithelial
compartment of the PCa human samples (Figure 1A; Figures
S1A and S1B available online). This is consistent with previous
observations suggesting that p62 is upregulated in many can-
cers, including lung cancer (Duran et al., 2008; Inoue et al.,
2012), liver cancer (Inami et al., 2011), glioblastoma (Galavotti
et al., 2013), breast cancer (Rolland et al., 2007; Thompson
et al., 2003), and kidney cancer (Li et al., 2013). However,
because those studies did not report on expression in the stro-
mal component, it is not clear whether p62 was downregulated
in the stroma in those samples, as we have shown in the samples
analyzed here. Moreover, bioinformatics analysis of public data
sets of stromal gene expression also demonstrated that p62
was significantly downregulated in the tumor stroma, compared
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Metabolic Suppressor Role of p62 in Stromawith normal stroma, in several types of cancers, including pros-
tate, breast, and colon cancers (Figure 1D). In addition, fluores-
cence-activated cell sorting (FACS) analysis of adult mouse
prostates showed that p62 is more highly expressed in cells of
the stroma than in those of basal or luminal lineages (Figures
1E–1G). Quantitative RT-PCR analyses of the sorted prostate
cell populations showed that transcripts for the basal marker
p63, the luminal cell marker Nkx3.1, and the stroma marker
vimentin were enriched in their corresponding cell populations,
demonstrating successful cell fractionation (Figures 1E and
1F). Of note, p62 expression was highly enriched in the stromal
compartment compared with the other two cell populations (Fig-
ure 1G). These results suggest that p62 could exert its effect as a
tumor suppressor in the tumor microenvironment, likely in the
stroma.
p62 Is a Suppressor of Inflammation and the CAF
Phenotype in the Tumor Microenvironment
To test whether p62 deficiency in the tumor microenvironment
is relevant to the transforming properties of epithelial cells, we
performed orthotopic injections of syngeneic murine PCa cells
(TRAMP-C2Re3) (Olson et al., 2006) into the prostates of wild-
type (WT) and p62 knockout (KO) mice and then assessed tumor
growth. The resulting tumors were bigger in the prostates of p62
KO mice than in those of WT mice (Figures 2A–2C), supporting
the notion that a loss of p62 in the tumor microenvironment pro-
motes PCa growth. We next carried out transcriptomic profiling
of the orthotopic tumors in the WT and p62 KO mice. NextBio
analysis revealed important correlations between genes upregu-
lated in the p62 KO orthotopic tumors with a gene signature
in the category of ‘‘response to wounding’’ (Figure S2A). In
addition, gene set enrichment analysis (GSEA) also identified
‘‘response to wounding’’ as significantly enriched of the gene
ontology (GO) biological-process categories (Figure 2D; Figures
S2B and S2C) and ‘‘stromal stimulation’’ in the C2 curated gene
set library (Figures S2D and S2E). Because CAFs acquire an
‘‘activated phenotype’’ during tumor progression that resembles
that of fibroblasts during the wound-healing repair process,
these results suggested that the p62 KO stroma is likewise acti-
vated (Barron and Rowley, 2012; Bissell and Radisky, 2001;
Franco and Hayward, 2012; Scha¨fer and Werner, 2008) and
has a more CAF-like phenotype than the WT stroma. In support
of this notion, we observed an increase in the expression of a
smoothmuscle actin (a-SMA) in sections from orthotopic tumors
in p62 KO mice compared to WT controls (Figure 2E), as well as
an increase in transforming growth factor b (TGF-b) transcripts
as determined by RT-PCR in the same samples (Figure 2F).
TGF-b and a-SMA are two bona fide markers of the CAF pheno-
type (Barron and Rowley, 2012; Franco and Hayward, 2012).
Consistent with this, Ingenuity Pathway Analysis identified
TGF-b1 as a predicted upstream regulator in the p62 KO ortho-
topic tumors (p = 1.47 3 107, activation Z score = 3.890). To
determine the potential cell-autonomous effect of p62 in this
important function, we used FACS to isolate prostate stromal
cells from mice of both genotypes, as described in Figures 1E
and 1F. Interestingly, we found that p62-deficient stromal
cells also showed characteristics of CAFs, as determined by
increased expression levels of a-SMA, TGF-b, and vimentin (Fig-
ure 2G). To facilitate subsequent studies, we generated prostatefibroblasts from WT and p62 KO mice and determined their
‘‘CAF activation’’ state. In these cells, the loss of p62 resulted
in increased CAF transcript markers (Figure 2H), as well as in
the secretion of TGF-b, as determined by ELISA (Figure 2I).
This is important because TGF-b is essential for the acquisition
and maintenance of the CAF/myofibroblast phenotype (Kojima
et al., 2010; Ostman and Augsten, 2009). Therefore, p62 loss
modifies the stroma by inducing a CAF phenotype, which in
turn drives tumor progression.
Further bioinformatics GSEA revealed a hyperinflammatory
phenotype in the p62 KO orthotopic tumors. That is, we found
‘‘humoral immune response’’ and ‘‘inflammatory response’’ as
second GO categories enriched in the p62 KO transcriptome
profile (Figure 2J; Figures S2F and S2G). RT-PCR analysis of
the tumors from p62 KO mice showed increases in the tran-
scripts of inflammatory cytokines such as IL-6, IL-1b, and kera-
tinocyte chemoattractant (Figure 2K), as well as in the secretion
of IL-6 as determined by ELISA (Figure 2L).We hypothesized that
IL-6 could be an important mediator of the stromal p62-depen-
dent signals that influence PCa progression in the epithelium.
To test this possibility, we carried out an orthotopic injection
experiment using p62/IL-6 double-KO (DKO) mice as hosts.
Notably, the increased tumor growth observed in p62 KO mice
was completely reversed in the DKO mice (Figures 2M and
2N), demonstrating that p62 plays a tumor-suppressive role in
the tumor microenvironment during PCa progression by inhibit-
ing CAF activation and blocking inflammation.
p62 in Stromal Fibroblasts Regulates an IL-6/TGF-b
Cascade Essential for Tumor Invasion
We next set up a 3D organotypic culture model that recapitu-
lates, in a genetically accessible system, the tumor microenvi-
ronment and its interactions with the tumor epithelial cell, closely
mimicking the physiological situation and the cellular architec-
ture (Gaggioli et al., 2007; Kim et al., 2013; Nystro¨m et al.,
2005; Ridky et al., 2010). Because our genome-wide transcrip-
tomic analysis suggested that the loss of p62 in the tumor
microenvironment is associated with a CAF-like signature, and
because fibroblasts are a critical component of the stroma, we
next tested whether p62 KO prostate fibroblasts were able to
recapitulate the in vivo phenotype in 3D organotypic cultures.
To do this, we cocultured in this organotypic system prostate
fibroblasts from p62 KO and WT mice with TRAMP-C2Re3
PCa cells (Figure 3A). Importantly, p62 KO prostate fibroblasts
(versus WT counterparts) enhanced the invasiveness and prolif-
eration index of PCa epithelial tumor cells (Figures 3B–3D).
Similar results were obtained with other PCa cell lines, such as
mouse Myc-CaP (Figure S3A), or human PC3 cells (Figure S3B).
Mouse fibroblasts from p62 KO mice also enhanced the inva-
siveness and proliferation index of human normal prostate
epithelial cells compared with similar organotypic cultures with
WT fibroblasts (Figure S3C). Altogether, this indicates that p62
deficiency in the stromal fibroblasts has a pivotal role in medi-
ating cancer cell proliferation and invasion.
To follow up on our findings that IL-6 levels were increased in
orthotopically injected tissues and that increased IL-6 expres-
sion was associated with enhanced tumorigenicity in vivo (Fig-
ures 2K–2N), we further investigated the role of this cytokine in
the protumorigenic microenvironment created by p62 deficiencyCancer Cell 26, 121–135, July 14, 2014 ª2014 Elsevier Inc. 123
Figure 2. IL-6 Is Required for p62’s Role in the Tumor Microenvironment
(A) Orthotopic injection of TRAMP-C2Re3 cells into the prostates of syngeneic WT and p62 KO mice. Orthotopic tumors were allowed to grow for two months.
(B and C) GU tract weight (B) and pictures (C) from (A); n = 5 or 6 mice per genotype. The scale bar represents 1 cm.
(D) ‘‘Response to wounding’’ GSEA plot of enrichment of gene expression in p62 KO orthotopic tumors.
(E) a-SMA staining of orthotopic tumors from WT and p62 KO mice. The scale bars represent 25 mm.
(F) RT-PCR of TGF-b in orthotopic tumors from WT and p62 KO mice (n = 3).
(G and H) RT-PCR of CAF markers (a-SMA, TGF-b, and vimentin) in FACS-sorted prostate stromal fraction fromWT and p62 KOmice (G) and in WT and p62 KO
prostate fibroblasts (H); n = 3.
(I) TGF-b production in prostate fibroblasts was determined by ELISA.
(J) GSEA plots of enrichment of gene expression in p62 KO orthotopic tumors.
(K) RT-PCR of inflammatory cytokines in orthotopic tumors of WT and p62 KO mice; n = 5 or 6 animals per group versus WT.
(L) IL-6 ELISA in fibroblasts.
(M andN) Orthotopic injection of TRAMP-C2Re3 cells into the prostates ofmice of different genotypes (n = 5 or 6mice). GUweights (M) and pictures (N). The scale
bar represents 1 cm.
*p < 0.05, **p < 0.01, ***p < 0.001. Results are presented as mean ± SEM. See also Figure S2.
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environment aremacrophages and stromal fibroblasts (Hanahan
and Coussens, 2012). Notably, 3D organotypic culture experi-124 Cancer Cell 26, 121–135, July 14, 2014 ª2014 Elsevier Inc.ments established that fibroblasts (Figures 3B and 3C), but
not macrophages (Figure S3D), from p62 KO mice recapitu-
lated the p62 KO phenotype in the orthotopic tissue grafting
Figure 3. p62-Deficient Stroma-Mediated Invasion Is IL-6 and TGF-b Dependent
(A) Schematic representation of 3D organotypic cultures.
(B) H&E-stained sections of TRAMP-C2Re3 cells cultured in an organotypic system in the presence of primary prostate fibroblasts from WT and p62 KO mice.
(C and D) Quantification of PCa cell invasion (C) and proliferation index (D) of experiment shown in (B); n = 4.
(E) H&E staining of organotypic gels combining Myc-CaP cells with prostate fibroblasts from mice of different genotypes (n = 4).
(F and G) Quantification of PCa cell invasion (F) and proliferation index (G) of experiment shown in (E); n = 4.
(H) H&E staining of organotypic gels combining Myc-CaP cells with prostate fibroblasts frommice WT and p62 KOmice in the presence or absence of the TGF-b
inhibitor SB431542 (10 mM).
(I and J) PCa cell invasion quantification (I) and proliferation index (J) of (H); n = 4.
(K) Invasion index determined by modified Boyden chamber assay with conditioned media from WT and p62 KO fibroblasts in the presence or absence of
SB431542 (10 mM); n = 3.
(L and M) RT-PCR of TGF-b (L) and a-SMA (M) mRNA levels in fibroblasts of mice of different genotypes (n = 4).
(N) IL-6 production by WT and p62 KO fibroblasts in the presence or absence of the TGF-b inhibitor SB431542 (n = 4).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Results are presented as mean ± SEM. The scale bars represent 100 mm. See also Figure S3.
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fibroblasts were used in the 3D system (Figures 3E–3G). Further-
more, when TGF-b signaling was inhibited by incubating the
organotypic cultures with the TGF-b inhibitor SB431542 (Inman
et al., 2002), the protumorigenic phenotype of p62-deficient
fibroblasts was reverted, consistent with the notion that TGF-b
is important for the CAF phenotype and PCa proliferation (Fig-ures 3H–3J). Likewise, the TGF-b inhibitor reverted the increased
invasion index of PCa cells incubated with p62-deficient fibro-
blast conditioned medium in a Boyden chamber invasion assay
(Figure 3K). Results shown in Figure S3E demonstrate the effec-
tiveness of this inhibitor to block the TGF-b pathway. Moreover,
the enhanced TGF-b production observed in the p62 KO fibro-
blasts, as well as that of a-SMA, was completely abrogated inCancer Cell 26, 121–135, July 14, 2014 ª2014 Elsevier Inc. 125
Figure 4. Metabolic Reprogramming in p62-Deficient Stroma
(A and B) Total intracellular levels of ROS in WT and p62 KO fibroblasts (A) and quantification (B); n = 4.
(C) IL-6 ELISA of WT and p62 KO fibroblasts treated with vehicle or the ROS scavenger BHA (100 mM) for 12 hr (n = 4).
(D and E) RT-PCR of NQO1 (D) and SOD1, SOD2, and FHC (E) mRNA levels in fibroblasts (n = 4).
(legend continued on next page)
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Metabolic Suppressor Role of p62 in Stromathe DKO fibroblasts (Figures 3L and 3M). Consistently, the
knockdown of IL-6 in p62 KO fibroblasts impaired IL-6 secretion
and, more important, also reverted TGF-b production and PCa
invasion (Figures S3F–S3H). Furthermore, incubation of p62/
IL-6 DKO fibroblasts with exogenously added IL-6 restored
TGF-b levels to those of p62 KO cells as well as PCa invasion
(Figure S3I and S3J). All this is consistent with a cell-autonomous
role of the p62-IL-6 axis in the control of the CAF phenotype.
However, incubation of p62 KO fibroblasts with the TGF-b
signaling inhibitor SB431542 did not affect the overproduction
of IL-6 in p62 KO fibroblasts (Figure 3N). These are important
observations that establish a sequential p62/IL-6/TGF-b axis in
the tumor fibroblastic compartment contributing to the control
of epithelial tumorigenesis during PCa progression.
p62Controls IL-6 Levels by RepressingReactiveOxygen
Species Production through Metabolic Reprogramming
We next sought to determine how p62 controls IL-6 production
in fibroblastic stromal cells and whether the mechanisms medi-
ating IL-6 production are relevant to stroma-driven tumorigen-
esis. It should be noted that p62 KO fibroblasts have increased
levels of reactive oxygen species (ROS) (Figures 4A and 4B)
and that the inhibition of ROS production (by the ROS scavenger
butylated hydroxyanisole [BHA]) completely reverts the IL-6
hyperproduction phenotype (Figure 4C). This indicates that the
mechanism whereby p62 represses IL-6 production in fibro-
blasts involves the control of ROS levels. It has previously
been reported that p62 can activate NF-kB and NRF2 (Duran
et al., 2008; Komatsu et al., 2010; Moscat and Diaz-Meco,
2009), which suggests that these molecules could play a role
in the ability of p62 to repress ROS production and the subse-
quent activation of IL-6. The expression of critical detoxifying
NF-kB- or NRF2-dependent genes (Figures 4D and 4E), as well
as the levels of the NRF2 inhibitor Keap1 (Figure 4F), was not
affected by the loss of p62 in fibroblasts. However, we found
that p62 KO fibroblasts displayed lower levels of reduced gluta-
thione (GSH) than the WT controls (Figure 4G). These are impor-
tant observations because GSH is central to the control of ROS
levels. In fact, treatment of p62 KO fibroblasts with the GSH
analog GSH-reduced ethyl ester (GEE) reduced IL-6 to levels
comparable with those of WT fibroblasts (Figure 4H). These
results demonstrate that the loss of p62 results in lower GSH
levels, thus promoting ROS accumulation, which is required for
IL-6 overproduction in p62-deficient fibroblasts.
We observed a striking decrease in the reduced nicotinamide
adenine dinucleotide phosphate (NADPH)/nicotinamide adenine
dinucleotide phosphate (NADP) ratio in p62-deficient fibroblasts(F) Immunoblot analysis of KEAP1 in cell lysates from WT and p62 KO fibroblast
(G) Cellular GSH levels in WT and p62 KO fibroblasts (n = 4).
(H) IL-6 ELISA of fibroblasts treated with increasing concentrations of the GSH a
(I) Cellular NADPH/NADP levels in WT and p62 KO fibroblasts (n = 4).
(J) Metabolic scheme depicting biosynthetic routes to NAPDH (yellow shading) a
(K) Glucose consumption, lactate secretion, and glutamine consumption rates d
(L) PPP flux estimates from metabolic flux analysis in WT and p62 KO fibroblast
(M) RT-PCR of GLUT1 mRNA (n = 4).
(N) Glutamate labeling inWTandp62KOfibroblasts grown in either [1,2-13C2]gluco
(O and P) RT-PCR of SLC7A5, SLC1A5, and GLS1 (O) and SLC7A11 (P) mRNA l
(Q) Labeling of serine and glycine from [1,213C2]glucose (n = 3).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Results are presented as mea(Figure 4I). This ratio provides additional information on the
cellular redox status, as the relative concentration of GSH versus
oxidized GSH depends on the cellular content of NADPH. Glyco-
lytic metabolism plays a critical role in maintaining NADPH
production through the oxidative pentose phosphate pathway
(PPP) (Figure 4J, yellow shading). Indeed, p62 KO cells exhibited
decreased glucose uptake and lactate secretion (Figure 4K). This
reduction in glycolytic rate resulted in decreased flux through the
oxidative PPP, as determined by stable isotope tracing with
[1,2-13C2]glucose (Figure 4L). These metabolic changes corre-
lated with a reduction in GLUT1 levels in p62-deficient fibro-
blasts (Figure 4M), providing evidence that transcriptional
changes associated with p62 loss influence metabolic flux.
Amino acids are critical for the production of GSH, a peptide
composed of glutamate, cysteine, and glycine (Figure 4J, pink
shading). Glutamine serves as an important precursor for gluta-
mate, and loss of p62 in fibroblasts leads to lower glutamine con-
sumption compared withWT cells (Figure 4K). We also observed
a decrease in the direct conversion of [U-13C5] glutamine to
glutamate in p62 KO fibroblasts, with a relative increase in the
fraction of glutamate derived from [1,2-13C2]glucose (Figure 4N).
In good agreement with these changes in glutaminemetabolism,
we observed reduced levels of the glutamine transporters
SLC7A5 and SLC1A5, as well as glutaminase-1 (GLS1) (Fig-
ure 4O), a critical enzyme in the pathway that catalyzes the con-
version of glutamine into glutamate (Figure 4J). Consistent with
reduced levels of GSH, p62 KO fibroblasts also exhibit a dra-
matic reduction in the levels of SLC7A11, the xCT cystine/gluta-
mate antiporter, which is the major driver of cystine uptake, a
critical and rate-limiting step in the synthesis of GSH in several
cell types, including fibroblasts (Figure 4P) (Bannai and Tateishi,
1986; Gout et al., 1997). Finally, we observed significant
decreases in labeling of both serine and glycine from [1,2-13C2]
glucose (Figure 4Q). Serine serves as a precursor to glycine
and cysteine (when synthesized from methionine), so this
decrease in label transfer provides evidence that there is less
demand for GSH synthesis in p62-deficient cells. These results
collectively demonstrate that loss of p62 in fibroblasts influences
metabolic pathways controlling cellular redox, including NADPH
production in the PPP and GSH synthesis.
p62 Is a Critical Regulator of c-Myc Levels
Previous data from other laboratories have established the crit-
ical role of c-Myc in the regulation of glutamineandglucosemeta-
bolism (Dang, 2012). We found significantly reduced levels of
c-Myc in p62 KO fibroblasts as well as in WT fibroblasts in which
p62 has been knocked down by small hairpin RNA (shRNA)s. Results are representative of three experiments.
nalog GEE (n = 4).
nd GSH (pink shading) from glucose and glutamine.
etermined by spent medium analysis from WT and p62 KO fibroblasts (n = 3).
cultures labeled with [1,2-13C2]glucose (n = 3).
se and unlabeled glutamine or [U-13C5]glutamine and unlabeled glucose (n = 3).
evels in WT and p62 KO fibroblasts (n = 3).
n ± SEM.
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Figure 5. c-Myc-Mediated Metabolism in p62-Deficient Stroma
(A–C) Immunoblot analysis of c-Myc levels in WT and p62 KO fibroblasts (A), in WT fibroblasts lentivirally infected with shRNA nontargeted control (shNT) or
shRNA specific for p62 (shp62) (B), and in p62 KO fibroblasts retrovirally infected with control vector (control) or with c-Myc expression vector (c-Myc) (C). Results
are representative of three experiments.
(D) IL-6 ELISA in control and c-Myc cells (n = 4) as in (C).
(E) RT-PCR of SLC7A5, SLC1A5, and GLS1 mRNA in control and c-Myc cells (n = 3).
(F) Intracellular GSH levels in control and c-Myc cells (n = 3).
(G) Immunoblot analysis of c-Myc and p-STAT3 in WT fibroblasts infected with shNT or shRNA for c-Myc (shMyc).
(legend continued on next page)
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mine transporters SLC7A5 and SLC1A5, and GLS1 (Figure 4O),
which are targets of c-Myc (Dang, 2012). Interestingly, ectopic
expression of c-Myc in p62 KO fibroblasts (Figure 5C) reverted
the p62-deficient phenotype in terms of IL-6 production (Fig-
ure 5D) and the levels of glutamine transporters and GLS1 (Fig-
ure 5E) and GSH (Figure 5F). On the contrary, c-Myc knockdown
in WT fibroblasts (Figure 5G) resulted in increased IL-6 produc-
tion at the mRNA and protein levels (Figures 5H and 5I). c-Myc
knockdown in fibroblasts led to decreased levels of GSH (Fig-
ure 5J), as well as enhanced PCa cell invasion and proliferation
in organotypic cell cultures (Figures 5K–5M). Also, the knock-
down of c-Myc in fibroblasts resulted in increased PCa cell inva-
sion index in a Boyden chamber assay (Figure 5N). Of note, this
cause-and-effect correlation between p62 deficiency, c-Myc
expression, and IL-6 productionwas also found in FACS-isolated
prostate stromal cells from WT and p62 KO mice (Figure 5O).
Collectively these results demonstrate that p62 repression of
c-Myc expression in the stroma fibroblasts accounts for its tumor
suppressive role in PCa.
IL-6 Is Regulated by a p62/mTORC1/c-Myc Cascade
Consistent with previously published observation (Duran et al.,
2011), we found that p62 KO cells displayed reduced mTORC1
activity (Figure 5P). We hypothesized that the reduction in
c-Myc levels found in p62 KO fibroblasts could be the conse-
quence of mTORC1 inhibition. Importantly, we rescued c-Myc
inhibition in p62 KO fibroblasts by expressing a permanently
active mutant of the small-guanosine triphosphatase RagB,
which is a critical activator of mTORC1 (Figure 5Q). IL-6 levels
were likewise reduced under these conditions (Figure 5R). These
results demonstrate that reduced mTORC1 activity in p62 KO
fibroblasts accounts for the low levels of c-Myc and the subse-
quent increase in IL-6 production in these mutant cells. Treat-
ment of WT fibroblasts with rapamycin or Torin, two different
inhibitors of mTORC1, effectively reduced c-Myc levels (Figures
5S and 5T), promoting a significant reduction in GSH levels
(Figure 5U) and a concomitant increase in IL-6 production (Fig-
ure 5V). Therefore, p62’s ability to regulate mTORC1 in the
stroma is essential for its control of the c-Myc/GSH/IL-6 axis.
p62 KO Mice Develop Prostate Hyperplasia and
Prostatic Intraepithelial Neoplasia upon Aging
On the basis of these results, we hypothesized that the loss of
p62 at an organismal level, which would include both the pros-(H and I) RT-PCR of IL-6 mRNA (H) and IL-6 ELISA (I) in the same cells (n = 3) as
(J) Quantification of intracellular GSH levels in WT shNT and shMyc cells (n = 3).
(K) H&E-stained organotypic gels of TRAMP-C2Re3 cells with shNT or shMyc fib
(L and M) Quantification of PCa cell invasion (L) and proliferation index (M) of ex
(N) Invasion index determined by modified Boyden chamber assay of Myc-CaP
(O) RT-PCR of c-Myc and IL-6 mRNA levels in FACS-isolated prostate stromal c
(P) Immunoblot analysis with the indicated antibodies of cell lysates of WT and p
(Q) Immunoblot analysis for the specified proteins of cell lysates from p62 KO fi
expression vector (RagBGTP). Results are representative of three experiments.
(R) IL-6 ELISA (n = 3) in cells shown in (Q).
(S and T) Immunoblot analysis of c-Myc and p-S6K in fibroblasts treated with ra
(U) Intracellular GSH levels in fibroblasts treated with Torin1.
(V) IL-6 ELISA in fibroblasts treated with Torin1 (n = 3).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Results are presented as meatate stroma and epithelium, might be sufficient to drive prostate
epithelium toward neoplasia. We characterized the prostates of
p62 KO mice by histological analysis, which revealed no abnor-
malities in development ormorphology at early stages. However,
at 9 months of age, prostates from p62 KO mice developed
hyperplasia, with a concomitant increase in Ki67 staining (Fig-
ures 6A and 6B). These lesions progressed to prostatic intraepi-
thelial neoplasia (PIN) at 1 year of age (Figure 6C). This indicated
that, whereas in xenograft experiments PCa epithelial cells with
reduced p62 displayed inhibited tumorigenesis (Duran et al.,
2011), the total loss of p62 in vivo promoted prostate epithelial
cell growth. These observations are in good agreement with
our model whereby p62 in the stromal fibroblasts normally acts
as a tumor suppressor, and the total KO of p62 results in p62-
deficient stromal fibroblasts that drive the prostate epithelium
to a malignancy-prone state. To further test this hypothesis,
we crossed total p62 KO mice with two well-established mouse
models of PCa (PTEN+/ and TRAMP+) (Di Cristofano et al.,
1998; Greenberg et al., 1995) and asked whether total ablation
of p62 inhibited or promoted prostate tumor development. Fig-
ures 6D and 6E show hematoxylin and eosin (H&E) analyses of
PTEN+//p62 KO prostrates demonstrating an increase in the
percentage of glandswith high-grade PIN at the age of 6months.
Furthermore, TRAMP+/p62 KO mice had reduced survival (Fig-
ure 6F), increased percentages of poorly differentiated adeno-
carcinoma (Figure 6G) and neuroendocrine tumors (Figure 6H),
as well as a larger number of metastases (Figure 6I), of which
a higher percentage were in the liver (Figure 6J). Consistent
with our model, prostate fibroblasts from PTEN+//p62 KO
mice showed increased IL-6 and reduced c-Myc expression
compared with those from p62-proficent PTEN+/ mice (Figures
S4A–S4C). Interestingly, immunohistochemical analysis of
prostates from PTEN+/ mice confirmed reduced expression of
p62 in the stromal compartment compared with those from WT
mice (Figure S4D). To further support the role of p62 deficiency
in the stroma in driving tumorigenesis in vivo, we coinjected syn-
geneic PCa cells (TRAMP-C2Re3) with WT or p62 KO fibroblasts
and assessed the effect that fibroblasts exert on tumor growth.
Tumors coinjected with p62 KO fibroblasts grew significantly
faster andwere larger than tumors inmice injectedwithWT fibro-
blasts, consistent with the cell-autonomous tumor-promoting
activity of p62-deficient fibroblasts on epithelial PCa cells (Fig-
ures 6K and 6L). In agreement with this, bromodeoxyuridine
(BrdU) incorporation was increased in the p62 KO fibroblast-
driven tumors (Figures 6M and 6N).in (G).
roblasts. The scale bar represents 100 mm.
periment shown in (K).
cells cocultured with shNT and shMyc fibroblasts.
ells from WT and p62 KO mice (n = 3).
62 KO fibroblasts.
broblasts retrovirally infected with control vector (control) or FLAG-RagBGTP
pamycin (S) or Torin1 (T) for 12 hr.
n ± SEM.
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Figure 6. p62 Deficiency Accelerates Prostate Tumor Progression in Different Mouse Models of Prostate Cancer
(A) Hyperplasia in the prostatic anterior lobe of p62 KO mice. H&E and Ki67 staining of prostates from 9-month-old WT and p62 KO mice (n = 5).
(B) Quantification of Ki67-positive cells in the prostate sections shown in (A). Results are the means ± SD of counts from 10 different fields per mouse (n = 5).
(C) PIN in the dorsolateral lobes of prostates from 12-month-old p62 KO mice.
(D) Representative examples of H&E staining of dorsolateral lobes of prostates from PTEN+/ and PTEN+//p62 KO mice at 6 months of age (n = 5).
(E) Percentage of glands with HG-PIN (n = 5 mice).
(F) Kaplan-Meier survival curve of TRAMP+ mice (n = 10), compared with TRAMP+/p62 KO mice (n = 15).
(G) Representative H&E staining of mouse prostate sections from TRAMP+ and TRAMP+/p62 KO mice (n = 10).
(H) Incidence of neuroendocrine tumors in TRAMP+ (n = 12) and TRAMP+/p62 KO mice (n = 19).
(I and J) Incidence of metastasis (I) and liver metastasis (J) in TRAMP+ compared with TRAMP+/p62 KO mice.
(K–M) Coinjection of syngeneic TRAMPC2-Re3 PCa cells with either WT or p62 KO fibroblasts in C57BL/6 mice. (K) Tumor volume assessed at different time
points after injection (n = 7 mice). (L) Tumor weight at 6 weeks after injection (n = 7 mice). (M) BrdU staining in tumor sections.
(N) Quantification of BrdU positive cells of (M).
Results are presented as mean ± SEM (n = 10). *p < 0.05, ****p < 0.001. The scale bars represent 25 mm. See also Figure S4.
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Figure 7. The p62-Myc-mTORC1 Cassette Is Downregulated in Prostate Tumor-Associated Stroma in Human Samples
(A) Myc levels are downregulated in the tumor stroma of human tissue samples. Data were collated from public data sets of gene expression in tumor stroma in
several human cancers: GSE34312 (prostate cancer) and GSE9014 (breast cancer). The p value, fold change of expression, and size of the sample (n) for each
study are indicated in the corresponding panels.
(B) Positive correlation between p62 and Myc levels in the stroma.
(C) Heatmap of mTORC1 signature selected from p62 neighboring genes in human stroma. p62 levels are indicated as SQSTM1.
(D and E) RT-PCR analysis of mTORC1 genes in WT and p62 KO fibroblasts (D) and in FACS sorted mouse prostate stromal fraction (E).
*p < 0.05, **p < 0.01, ***p < 0.001. Results are presented as mean ± SEM (n = 3). See also Figure S5.
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Stroma
To determine whether the identified link between p62 and c-Myc
through mTORC1 has relevance to the role of the stroma in hu-
man cancer, we used bioinformatics to analyze c-Myc transcript
levels in two sets of human gene-expression arrays from pros-
tate and breast cancer stroma. Stroma of human tumors
displayed reduced levels of c-Myc (Figure 7A), and there was
a statistically significant correlation between c-Myc and p62
expression in tumor stroma (Figure 7B), emphasizing the clinical
relevance of the p62-Myc connection in the stroma. To further
explore the link between p62 and mTORC1 in the tumor stroma
of human cancers, we identified expression neighbors of p62.
We developed this gene signature by using the human cancer
stroma data set shown in Figure 7A, in which we classified
tumors on the basis of p62 expression levels and selected for
analysis only those samples in the top and bottom 25%. Interest-
ingly, this analysis revealed a statistically significant correlation
between p62 expression and that of genes previously reported
to be controlled by mTORC1 activity (Figure 7C; Figure S5)(Pen˜a-Llopis et al., 2011). We determined the expression levels
of a selection of these genes by RT-PCR and found that their
expression was reduced in p62 KO fibroblasts compared with
WT (Figure 7D). The same results were obtained when these
were analyzed in prostate stromal cell preparations from p62
KO and WT mice (Figure 7E). Furthermore, we found a clear sta-
tistically significant correlation between p62 expression and that
of these genes in human cancer stroma (Figures S5B–S5H). Alto-
gether, these results demonstrate that the p62/mTORC1/c-Myc
connection is not only relevant in the mouse prostate stroma but
it is also important in human cancer stroma.
DISCUSSION
Tumorigenesis is a slow process that is initiated by the succes-
sive accumulation of genetic and epigenetic changes that result
in the activation of cell growth and survival genes and the inacti-
vation of tumor suppressors (Hanahan and Weinberg, 2011).
However, for tumor development to take place, initiation is not
sufficient. Other signals are required to drive tumor promotionCancer Cell 26, 121–135, July 14, 2014 ª2014 Elsevier Inc. 131
Figure 8. Stromal Activation by p62 Deficiency in Cancer
Tumor epithelium promotes the downregulation of p62 in stromal fibroblasts,
leading to reduced mTORC1 activity and c-Myc expression, which results
in impaired metabolic detoxification and the subsequent release of ROS and
IL-6. An autocrine pathway promotes TGF-b and the induction of CAF
phenotype, which further increases epithelial invasion and tumorigenesis.
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stage. The progression phase is most likely orchestrated via
the tumor microenvironment by nonepithelial cells in which
metabolic stress and inflammation create an environment in
which epithelial tumor-derived cells propagate and acquire
more aggressive phenotypes (Hanahan and Coussens, 2012;
Hanahan and Weinberg, 2011). Immune cells, such as tumor-
associated macrophages, are among the cell types in the tumor
microenvironment that contribute to inflammation (Coussens
and Werb, 2002; Johansson et al., 2008). On the other hand, a
crosstalk between metabolic pathways in the stromal and
epithelial compartments of the tumor may drive the survival
and growth of epithelial cancer cells (Lisanti et al., 2013). How-
ever, it has not been thoroughly investigated whether metabolic
reprogramming in the stromal cells of the tumor microenviron-
ment exerts any control over inflammation and the malignant
characteristics of the transformed epithelium.
Here we demonstrate that the inactivation of mTORC1 in p62-
deficient stromal fibroblasts results in metabolic reprogramming
through c-Myc inactivation (Figure 8). This reprogramming leads
to increased levels of IL-6, which promotes epithelial cell
invasion and proliferation. Therefore, because of its regulation
of mTORC1, p62 emerges as a tumor suppressor that acts by
regulating c-Myc and thus inducing an inflammatory response.
These results are in marked contrast to the role played by p62
and mTORC1 in epithelial cancer cells. That is, we have recently
demonstrated that p62 inactivation in PCa and lung adenocarci-
noma epithelial cells inhibits the proliferation and tumorigenic
properties of these cells and correlates with decreasedmTORC1
activation. Moreover, the increased IL-6 phenotype can be re-
verted by expression of a permanently active mutant of the
mTORC1 activator RagB. This has important implications from
a therapeutic point of view because inhibition of p62 and/or132 Cancer Cell 26, 121–135, July 14, 2014 ª2014 Elsevier Inc.mTORC1 may result in opposite effects in the stroma and
the epithelium of the tumor, thus reducing the efficacy of broadly
applied mTORC1-based chemotherapeutic approaches. In
this regard, these results are reminiscent of the dual role that
mTORC1 might play as a regulator of autophagy, which can
have a tumor-suppressing or a tumor-promoting effect, depend-
ing of the stage of the tumor (Guo et al., 2013; Levine and
Kroemer, 2008), and also on whether the manipulation takes
place in the epithelium or in the stroma (Lisanti et al., 2013).
Our data using KO mice clearly reveal that p62 deficiency cre-
ates a protumorigenic environment for p62-proficient PCa cells
in orthotopic experiments and also show that, even under normal
conditions, it drives PIN formation in the endogenous epithelium
in the absence of any other induced mutations. Furthermore, in
two PCa models, the lack of p62 at an organismal level results
in increased tumorigenesis, despite the fact that p62 is absent
not only in the stroma but also in the transformed epithelium.
These results are very important because they demonstrate
that even though p62 is required for epithelial cancer cells to pro-
liferate in vitro and in xenografts (Duran et al., 2011), the p62-
deficient tumor microenvironment overrides the requirement
for p62 in the epithelium. Our in vitro and in vivo findings establish
that increased IL-6 levels generated by stromal fibroblasts are a
critical event in that process. Therefore, it can be predicted that
total ablation of p62 at an organismal level, either genetically or
pharmacologically, may increase tumorigenesis, rather than in-
hibiting it, depending on the contribution of the stroma and the
ability of p62 deficiency to reprogram stromal metabolism to
generate ROS and inflammation. Our data shown here demon-
strate that this is the case in prostate tumorigenesis and suggest
that it could be a relevant mechanism in other tumor types as
well. The proinflammatorymicroenvironment in the p62-deficient
stroma results in a CAF-activated phenotype that is maintained
by stromal TGF-b production. This is consistent with previous
results in colon cancer demonstrating that a TGF-b-activated
tumor microenvironment is critical for fully aggressive cancer
cells to metastasize (Calon et al., 2012).
Metabolic reprogramming in cancer is emerging as a central
process in tumor cell survival and growth (DeBerardinis and
Thompson, 2012; Metallo and Vander Heiden, 2013; Vander Hei-
den, 2013). The so-called Warburg effect supports the impor-
tance of an atypical glucose metabolism tailored to the cancer
cell’s need for efficient anabolic utilization of nutrients (Vander
Heiden et al., 2009). More recently, different types of reprogram-
ming events have been unveiled that constitute specific re-
sponses of the tumor cell to a nutrient-deficient environment.
These include the metabolism of serine or the utilization of the
PPP to alleviate oxidative stress conditions during tumorigenesis
(Locasale, 2013; Ma et al., 2013; Possemato et al., 2011; Vander
Heiden et al., 2010). In the current study, we show that metabolic
reprogramming triggered by p62 deficiency in the tumor stroma
is critical for the creation of a protumorigenic inflammatory envi-
ronment driven by IL-6. Moreover, we have shown that this in-
volves an mTORC1/c-Myc/ROS cascade that is controlled by
p62. In this regard, previous results from our and other labora-
tories have shown that p62 represses ROS by inducing the acti-
vation of NF-kB- or NRF2-dependent detoxifying molecules
(Duran et al., 2008; Komatsu et al., 2010; Ling et al., 2012). Sur-
prisingly, neither of these two transcription factors nor Keap1
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Metabolic Suppressor Role of p62 in Stromalevels were affected in p62-deficient stromal fibroblasts, indi-
cating that p62 may use diverse cascades in different cellular
compartments of the tumor. Interestingly, our previous data
demonstrate that under conditions of Ras-induced transforma-
tion, p62 deficiency leads to increased cell death and reduced
tumorigenesis due to enhanced ROS production (Duran et al.,
2008). In contrast, we show here that the enhanced ROS
observed in the untransformed stromal fibroblasts does not
result in increased cell death but rather in the creation of a proin-
flammatory phenotype. The main conclusion of these results is
that increased ROS production induced by p62 deficiency has
different outcomes depending on the cell type and the mecha-
nisms whereby ROS is produced. The outcome also depends
on whether or not the levels of ROS are high enough to engage
a c-Jun N-terminal kinase-driven cell-death pathway, as found
in the Ras-tumor cell, as opposed to increased IL-6 production
and a protumorigenic effect on epithelial cells, as we demon-
strated in the stromal nontransformed fibroblasts.
Importantly, we were able to show that the implication of the
p62/mTORC1/c-Myc cascade is relevant not only in mouse
model systems but also in human samples, in which this pathway
is inactivated in the tumor stroma. Therefore, our findings sup-
port amore comprehensive approachwhen devising therapeutic
strategies in cancer, which should take into account not only the
altered pathways in the transformed epithelial compartment
but also how the inhibition of these cascades might affect the
surrounding stroma. Our observations suggest that pharmaco-
logical inhibition of IL-6 and/or TGF-b to target stromal activa-
tion could be beneficial in combination with epithelial-targeted
therapies.
EXPERIMENTAL PROCEDURES
Mice
WT, p62 KO, PTEN+/, and TRAMP+ mice were previously described (Dura´n
et al., 2004; Di Cristofano et al., 1998; Greenberg et al., 1995). All mouse strains
were generated in a C57BL/6 background. All mice were born and maintained
under pathogen-free conditions. All genotyping was done by PCR. Mice were
sacrificed and genitourinary (GU) sections were dissected. Mice were injected
with 5-bromo-20-deoxyuridine intraperitoneally and sacrificed 2 hr after injec-
tion. Animal handling and experimental procedures conformed to institutional
guidelines (Sanford-Burnham Medical Research Institute Institutional Animal
Care and Use Committee).
Cell Lysis and Western Immunoblotting
Cells were rinsed once with ice-cold PBS and lysed in radioimmunoprecipita-
tion assay buffer (1 3 PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 1 mM phenyl methyl sulfonyl fluoride, and protease inhibitors).
Cell extracts were denatured, subjected to 8% to 14%SDS-PAGE, transferred
to nitrocellulose-enhanced chemiluminescence membranes (GE Healthcare),
and immunoblotted with the specific antibodies. Chemiluminescence was
used to detect the proteins (Thermo Scientific).
Statistical Analysis
Significant differences between groups were determined using Student’s
t test. Scoring of immunostaining of human prostate tissue microarrays was
analyzed using Fisher’s exact test. The significance level for statistical testing
was set at p < 0.05.
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